These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27917873)

  • 1. Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model.
    Ye SF; Li J; Ji SM; Zeng HH; Lu W
    Acta Pharmacol Sin; 2017 Feb; 38(2):223-232. PubMed ID: 27917873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of plasma thioredoxin reductase activity to growth of H22 hepatocellular carcinoma xenografts in Kunming mice].
    Tan Q; Ren XY; Li J; Wang F; Deng SJ; Zeng HH
    Ai Zheng; 2009 May; 28(5):472-7. PubMed ID: 19624873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells.
    Zheng X; Xu W; Sun R; Yin H; Dong C; Zeng H
    Chem Biol Interact; 2017 Sep; 275():74-85. PubMed ID: 28757135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
    Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
    Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.
    Tan Q; Li J; Yin HW; Wang LH; Tang WC; Zhao F; Liu XM; Zeng HH
    Invest New Drugs; 2010 Jun; 28(3):205-15. PubMed ID: 19271154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis.
    Ye SF; Yang Y; Wu L; Ma WW; Zeng HH
    J Zhejiang Univ Sci B; 2017 May; 18(5):373-382. PubMed ID: 28471109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines.
    Zhao F; Yan J; Deng S; Lan L; He F; Kuang B; Zeng H
    Cancer Lett; 2006 May; 236(1):46-53. PubMed ID: 15982805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity.
    Yin H; Li J; Xiong K; Wang L; Wang T; Tan Q; Fu J; Ren X; Zeng H
    Differentiation; 2011 Jan; 81(1):49-56. PubMed ID: 20864247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
    Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen.
    Zheng X; Chen Y; Bai M; Liu Y; Xu B; Sun R; Zeng H
    Free Radic Biol Med; 2019 Feb; 131():7-17. PubMed ID: 30496814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of ethaselen and selenite treatment against A549 human non-small cell lung cancer cells.
    Xu W; Ma WW; Zeng HH
    Asian Pac J Cancer Prev; 2014; 15(17):7129-35. PubMed ID: 25227802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.
    Wang L; Fu JN; Wang JY; Jin CJ; Ren XY; Tan Q; Li J; Yin HW; Xiong K; Wang TY; Liu XM; Zeng HH
    Anticancer Drugs; 2011 Sep; 22(8):732-40. PubMed ID: 21562407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo.
    Xing F; Li S; Ge X; Wang C; Zeng H; Li D; Dong L
    Oral Oncol; 2008 Oct; 44(10):963-9. PubMed ID: 18282784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines.
    Shi C; Yu L; Yang F; Yan J; Zeng H
    Biochem Biophys Res Commun; 2003 Sep; 309(3):578-83. PubMed ID: 12963029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
    Yan J; Xu Y; Jin X; Zhang Q; Ouyang F; Han L; Zhan M; Li X; Liang B; Huang X
    Eur J Med Chem; 2022 Jan; 227():113897. PubMed ID: 34649064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.
    Fu JN; Li J; Tan Q; Yin HW; Xiong K; Wang TY; Ren XY; Zeng HH
    Invest New Drugs; 2011 Aug; 29(4):627-36. PubMed ID: 20195699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells.
    Peng ZF; Lan LX; Zhao F; Li J; Tan Q; Yin HW; Zeng HH
    J Zhejiang Univ Sci B; 2008 Jan; 9(1):16-21. PubMed ID: 18196608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy.
    Qian J; Xu Z; Meng C; Liu J; Hsu PL; Li Y; Zhu W; Yang Y; Morris-Natschke SL; Lee KH; Zhang Y; Ling Y
    Eur J Med Chem; 2020 Oct; 204():112610. PubMed ID: 32736231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
    Wang X; Zhang J; Xu T
    Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.